title: Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
abstract: Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy.
authors.affiliation: Section of Cardiology, Cardiac Sciences Department, St Boniface General Hospital, 401 Tache Avenue, Winnipeg, Manitoba, Canada.
authors.forename: R A
authors.initials: RA
authors.lastname: Ducas
authors.forename: M D
authors.initials: MD
authors.lastname: Seftel
authors.forename: J
authors.initials: J
authors.lastname: Ducas
authors.forename: C
authors.initials: C
authors.lastname: Seifer
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D008274:Magnesium / Q000627:therapeutic use; D008350:Manitoba; D008790:Metoprolol / Q000627:therapeutic use; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D017180:Tachycardia, Ventricular / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D008790:Metoprolol; D008274:Magnesium; D011188:Potassium; D000077237:Arsenic Trioxide